image description

Tag: Equillium

LRA-Funded Research Uncovers a Novel Pathway for Lupus Nephritis

January 28, 2022 The investigators from The Accelerated Medicines Partnership® Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP® RA/SLE) Program, in collaboration with Drs. Chaim Putterman from the Albert Einstein College of Medicine and Chandra Mohan from the University of Houston, and the biotechnology company Equillium have discovered an immune pathway that plays an important role […] Read More

LRA Celebrates Major Research Breakthroughs in 2019

January 7, 2020 2019 was a phenomenal, breakthrough year for lupus research on both the clinical development and basic science fronts. The Lupus Research Alliance (LRA) is incredibly proud that every new discovery leading to a brand new medicine for lupus had its origin in work funded by LRA years ago. The past 12 months delivered many […] Read More

LRA Pleased to Share News of Lupus Nephritis Clinical Trial Launch

October 1, 2019 The Lupus Research Alliance is pleased to share news about the launch of EQUALISE, a Phase 1b trial that will evaluate the safety and tolerability of an experimental compound itolizumab at various doses in a small group of patients with systemic lupus erythematosus (SLE) and lupus nephritis. Sponsored by the biotechnology company […] Read More

LRA-Funded Researcher Finds New Biomarkers for Lupus Nephritis

August 7, 2019 Dr. Chandra Mohan discovered that blood clotting proteins are higher in the urine of people with lupus nephritis, announced University of Houston. His work showed that both proteins that promote clotting and those that work to dissolve them are involved.  He began examining these proteins because people with lupus and lupus nephritis […] Read More